2. Search Result
Search Result
Results for "

viral RNA molecules

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156215
    NCI-B16

    		HCV Infection
    NCI-B16 is a small molecule RNA binder and inhibits HCV viral replication .
    NCI-B16
  • HY-108986
    JFD00244

    		Sirtuin SARS-CoV Cancer
    JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2 .
    JFD00244
  • HY-158028
    PAN endonuclease-IN-2

    		Influenza Virus Infection
    PAN endonuclease-IN-2 (compound T-31) is a PAN endonuclease inhibitor (IC50: 0.15 μM) and antiviral agent with broad-spectrum anti- Influenza activity. PAN is the N-terminal PA subunit of the polymerase-RNA complex and the dependent endonuclease (CEN) active site. PAN initiates RNA replication by promoting cleavage of the RNA strand and allowing the polymerase to begin synthesizing new RNA molecules. PAN endonuclease-IN-2 targets both the influenza HA and RdRp complexes, thereby interfering with viral entry into host cells and viral replication .
    PAN endonuclease-IN-2
  • HY-169123
    DMDA-PatA

    		Eukaryotic Initiation Factor (eIF) Infection Cancer
    DMDA-PatA is a small-molecule eIF4A inhibitor that represses translation in an mRNA-selective and ATP-independent manner by clamping eIF4A, a DEAD-box RNA binding protein, onto GNG motifs. DMDA-PatA is promising for research of cancers and viral infections .
    DMDA-PatA
  • HY-136797
    BP13944

    		Others Infection
    BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future.
    BP13944

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: